|
CPEB4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.41059999739335E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.557700E-02 |
| Stage1-vs-Stage3 |
2.782600E-01 |
| Stage1-vs-Stage4 |
6.180500E-03 |
| Stage2-vs-Stage3 |
1.246350E-02 |
| Stage2-vs-Stage4 |
3.768700E-04 |
| Stage3-vs-Stage4 |
9.212400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.628000E-04 |
| Normal-vs-Asian |
1.89337434619574E-12 |
| Caucasian-vs-AfricanAmerican |
4.121000E-01 |
| Caucasian-vs-Asian |
8.580600E-01 |
| AfricanAmerican-vs-Asian |
4.005400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.066350E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.18910437052477E-11 |
| Normal-vs-Age(81-100Yrs) |
2.176200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.193200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.357200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.039600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.667760E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.783200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.789400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.564300E-04 |
| Classical-VS-Follicular |
1.6975499999905E-05 |
| Classical-VS-Other |
8.409200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.77520006974896E-10 |
| Tall-VS-Other |
3.785600E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.211830E-01 |
| Follicular-VS-Normal |
4.67929999969918E-07 |
| Other-VS-Normal |
9.9771999999998E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
6.898400E-03 |
|
|
